Associated Papers
Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma.
Liu T et al.
Cold Spring Harbor Molecular Case Studies, 2021
Select a paper to view details